Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation

Abstract Background Hepatocellular carcinoma (HCC) remains one of the most challenging malignancies with persistently dismal long-term survival outcomes despite multidisciplinary advances in diagnostic and therapeutic strategies. Cinobufacini preparations have garnered increasing attention as adjunc...

Full description

Bibliographic Details
Published in:Journal of Experimental & Clinical Cancer Research
Main Authors: Jingwen Liu, Jia Jiang, Ju Huang, Zhi-E Fang, Lexi Liu, Yong Liu, Weiqi Nian, Jianyuan Tang, Zhilei Wang
Format: Article
Language:English
Published: BMC 2025-08-01
Subjects:
Hepatocellular carcinoma
Cinobufacini preparations
Bufalin
RAS/RAF/MEK/ERK
EGFR
Online Access:https://doi.org/10.1186/s13046-025-03531-3

Internet

https://doi.org/10.1186/s13046-025-03531-3

Similar Items